Welichem Biotech Successfully Moves to Higher Dose for Phase I Clinical Trials

BURNABY, BC, Sep. 7 /CNW/ - Welichem Biotech Inc. ("WBI" or the "Company") (TSX-V: WBI - News) is very pleased to report that the Phase I Clinical Trials of the Company’s anti-psoriasis drug candidate, WBI-1001, are running as planned in Montreal, Quebec. The trials consist of six separate cohorts. All six patients in Cohort I have been treated with WBI-1001 for at least fourteen days and none has experienced any adverse side effects. Patients for Cohort II, in which the dosage level will be increased, are now being recruited.

The Company notes that Mr. Andrew Baren, the company’s investor relations manager, recently left Welichem to pursue personal interests. We thank him for his efforts on our behalf and we wish him well.

The Company seeks Safe Harbour.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

For further information

York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com

Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com

--------------------------------------------------------------------------------

Source: Welichem Biotech Inc.